|
|
|
Insider
Information: |
Spiegel Robert J. |
Relationship: |
Director |
City: |
Menlo Park |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
300,930 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$739,990 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
300,930 |
|
|
Total
Value |
$739,990 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Geron Corporation |
GERN |
Director |
2023-12-29 |
164,040 |
2010-07-09 |
0 |
Premium* |
|
PTC Therapeutics, Inc. |
PTCT |
Chief Medical Officer |
2015-03-13 |
3,239 |
|
0 |
Premium* |
|
PDS Biotechnology Corp |
PDSB |
Director |
2019-03-15 |
48,661 |
2015-10-06 |
0 |
Premium* |
|
Sucampo Pharmaceuticals, Inc. |
SCMP |
Director |
2018-02-13 |
0 |
2016-06-02 |
0 |
Premium* |
|
Cyclacel Pharmaceuticals Inc |
CYCC |
Director |
2023-06-30 |
39,415 |
2021-06-15 |
0 |
Premium* |
|
Athenex, Inc. |
ATNX |
Director |
2023-04-21 |
4,592 |
2022-04-08 |
0 |
Premium* |
|
Renovorx, Inc. |
RNXT |
Director |
2024-01-26 |
40,983 |
2024-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GERN |
Geron Corporation |
Director |
|
2023-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,390 |
160,634 |
0 |
- |
|
GERN |
Geron Corporation |
Director |
|
2023-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,406 |
164,040 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Medical Officer |
|
2015-03-13 |
4 |
AS |
$75.10 |
$77,355 |
D/D |
(1,030) |
3,239 |
0 |
- |
|
GERN |
Geron Corporation |
Director |
|
2018-09-13 |
4 |
AS |
$6.85 |
$1,198,750 |
D/D |
(175,000) |
65,576 |
0 |
- |
|
PDSB |
PDS Biotechnology Corp |
Director |
|
2015-10-06 |
4 |
B |
$11.00 |
$33,000 |
D/D |
3,000 |
37,112 |
2.39 |
- |
|
RNXT |
Renovorx, Inc. |
Director |
|
2024-01-26 |
4 |
B |
$0.00 |
$0 |
D/D |
40,983 |
40,983 |
2.31 |
- |
|
GERN |
Geron Corporation |
Director |
|
2012-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,500) |
63,838 |
0 |
- |
|
GERN |
Geron Corporation |
Director |
|
2013-07-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,000) |
30,347 |
0 |
- |
|
GERN |
Geron Corporation |
Director |
|
2014-06-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,500) |
46,527 |
0 |
- |
|
SCMP |
Sucampo Pharmaceuticals, ... |
Director |
|
2018-02-13 |
4 |
D |
$18.00 |
$92,340 |
D/D |
(5,130) |
0 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Medical OfficerOfficer |
|
2014-01-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,455 |
|
- |
|
GERN |
Geron Corporation |
Director |
|
2018-09-13 |
4 |
OE |
$1.10 |
$516,550 |
D/D |
175,000 |
100,576 |
0 |
- |
|
PDSB |
PDS Biotechnology Corp |
Director |
|
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
48,661 |
0 |
- |
|
ATNX |
Athenex, Inc. |
Director |
|
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
17,247 |
0 |
- |
|
PTCT |
PTC Therapeutics, Inc. |
Chief Medical Officer |
|
2014-03-13 |
4 |
S |
$31.75 |
$37,656 |
D/D |
(1,186) |
4,269 |
0 |
- |
|
65 Records found
|
|
Page 3 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|